Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, to ...

(Reuters) -Drugmaker Eli Lilly is in advanced talks to acquire gene-editing startup Verve Therapeutics for up to $1.3 billion ...

The budget cuts threaten global progress on everything from heart disease to H.I.V. — and could affect American drug ...

The Israel-Iran clash seemingly has no end in sight — a prospect that does not seem to be panicking the markets.

The IPO comes just a few weeks after Caris raised $168 million in a private financing round that took the total raised by the ...

Fat steers and heifers filled the pens at the Finney County Fairgrounds in the early morning hours of June 3, waiting to be ...

Company scales leadership to accelerate growth and reinforce market position as the leader in AI-powered life sciences procurement ...

The US Supreme Court on Monday declined to review a federal appeals court decision that Merck Sharpe & Dohme Corp. couldn’t ...

That challenge, of finding or building good, useable data sets, is also one of the biggest differentiators in an increasingly ...

AQR Capital's Q1'25 portfolio hits $97.07B, with top picks in AAPL, NVDA, & AMZN. Active portfolio adjustments show a ...

A Roots Analysis study showed the market for ADC manufacturing is $1.79 billion today, but is expected to grow to $7 billion ...

Artificial intelligence (AI) is no longer a distant innovation — it's now a core part of the pharmaceutical and life sciences ...